How to Cite
Abstract
This article presents the findings of a regional expert council meeting on renal cell carcinoma (RCC) in Siberia and the Far East, held on May 20, 2022, in Novosibirsk. The meeting aimed to coordinate patient management tactics in systemic therapy for advanced RCC (aRCC), discuss clinical experience with immune-targeted regimens, and obtain expert opinions on the study of lenvatinib in combination with pembrolizumab for aRCC patients. The council discussed different approaches to treatment based on clinical guidelines and real world practice, the provision of modern first-line combination therapy options for patients in Siberia and the Far East, and the specific routing of this patient cohort. The agenda included identifying the ideal patient profile for combined immune-targeted therapy with lenvatinib and pembrolizumab, with emphasis on toxicity control. The meeting also addressed significant pharmacoeconomic issues and ways to tackle them.
References
Motzer RJ, Porta C, Eto M, et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). J Clin Oncol. 2021;39(suppl 6):269. doi:10.1200/JCO.2021.39.6_suppl.269.
Зуков Р.А., Черняев Д.В., Зулкайдарова А.Р. Применение комбинированных режимов терапии в лечении метастатического почечно-клеточного рака. Современная Онкология. 2022;24(2):191–198 [Zukov RA, Chernyaev DV, Zulkaidarova AR. Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review. Journal of Modern Oncology. 2022;24(2):191–198 (In Russ.)]. doi:10.26442/18151434.2022.2.201720.
Powles T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):15111519. doi:10.1016/j.annonc.2021.09.014.
Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(1):7190. doi:10.6004/jnccn.2022.0001.
Носов Д.А., Алексеев Б.Я., Гладков О.А., и др. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли. 2021;11(3s2-1):513522 [Nosov DA, Alekseev BYa, Gladkov OA, et al. Practical recommendations for drug treatment of renal cell cancer. Malignant tumours. 2021;11(3s2-1):513522 (In Russ.)]. doi:10.18027/2224-5057-2021-11-3s2-31.
Ljungberg B (Chair), Albiges L, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2021 Update. EAU Annual Congress. Milan. 2021.
Клинические рекомендации по лечению рака паренхимы почки у взрослых, утверждены Российским обществом урологов, подготовлены совместно со специалистами Российского общества онкоурологов и Ассоциации онкологов России. Доступны на сайте Министерства Здравоохранения Российской Федерации. [Clinical guidelines for the treatment of renal parenchymal cancer in adults, approved by the Russian Urological Society, prepared in collaboration with specialists from the Russian Association of Oncological Urology and the Association of Oncologists of Russia. Available on the website of the Ministry of Health of the Russian Federation. (In Russ.)]. Available at: https://oncology-association.ru/wp-content/uploads/2022/03/rak-parenhimy-pochki.pdf?ysclid=lfqylidhij247624058.
Lombardi P, Filetti M, Falcone R, et al. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Cancer Treat Rev. 2022;106:102377. doi:10.1016/j.ctrv.2022.102377.
Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. doi:10.1136/esmoopen-2020-001079.
Lee J-L, Ziobro M, Suarez C, et al. First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): updated follow-up for KEYNOTE-427 cohort B. J Clin Oncol. 2020;38:Suppl:50345034.
Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2020;21(12):e553]. Lancet Oncol. 2020;21(12):15631573. doi:10.1016/S1470-2045(20)30436-8.
Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829841. doi:10.1056/NEJMoa2026982.
Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New England Journal of Medicine. 2021;384(14):1289–300. doi:10.1056/nejmoa2035716.
Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study [published online ahead of print, 2022 Apr 27]. Lancet Oncol. 2022;S14702045(22)00212-1. doi:10.1016/S1470-2045(22)00212-1.
Инструкция по медицинскому применению препарата Ленвима® (ленватиниб): РУ ЛП – 003398 от 29.12.2015, с изменениями от 29.03.2022. [Instructions for the medical use of Lenvima® (lenvatinib): RU PL – 003398 dated 29.12.2015, as amended on 29.03.2022 (In Russ.)].
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2023